ERYTECH Pharma S.A. (ERYP) Research

ERYTECH Pharma S.A. is a biopharmaceutical company specializing in the clinical development of red blood cell-based treatments for various cancers and orphan diseases. Its operations are based in France and the United States. The company's most advanced investigational therapy, eryaspase, is currently undergoing Phase 3 clinical trials for second-line pancreatic cancer, and Phase 2 studies for patients with triple-negative breast cancer and second-line acute lymphoblastic leukemia. Furthermore, ERYTECH is developing erymethionase, a preclinical candidate that employs methionine-γ-lyase encapsulated in red blood cells to target methionine-dependent tumors. Founded in 2004, the firm's headquarters are located in Lyon, France.

Market snapshot

Symbol
ERYP
Price
$0.78
Day change
+1.30%
Market cap
$1.0M
P/E ratio
-0.02x
52-week range
0.3-1.472
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • AlloVir, Inc. (ALVR)
  • bluebird bio, Inc. (BLUE)
  • Cerecor Inc. (CERC)
  • GreenLight Biosciences Holdings (GRNA)
  • Kronos Bio, Inc. (KRON)
  • Magenta Therapeutics, Inc. (MGTA)
  • Pluristem Therapeutics Inc. (PSTI)
  • Lunai Bioworks Inc. (RENB)

Open ERYTECH Pharma S.A. (ERYP) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.